Ryplazim® (plasminogen, human-tvmh)

Ryplazim is covered only for the FDA‑approved indication of plasminogen deficiency type 1 (hypoplasminogenemia) and is not covered for other diagnoses or uses. Coverage requires biallelic PLG mutations, a baseline plasminogen activity ≤45%, a clinical history of compatible lesions/symptoms, hematologist prescription or consultation, initial approval for 3 months (recommended dosing 6.6 mg/kg IV every 2–4 days), and reauthorization (up to 12 months) only with documented clinical response or an absolute ≥10% increase in trough plasminogen activity over baseline.

"Dosing recommendation (coverage expectation): 6."

Sign up to see full coverage criteria, indications, and limitations.